FAVORABLE CLINICAL-NEUROLOGICAL OUTCOMES IN CHILDREN WITH PHENYLKETONURIA RECEIVING TIMELY DIETARY THERAPY
DOI:
https://doi.org/10.37547/Keywords:
clinical observation, dietary adherence, neurological development, pediatric neurology, phenylalanine control, phenylketonuriaAbstract
Uncontrolled phenylalanine metabolism threatens brain maturation, cognitive functioning, and neurological status during childhood, making timely dietary initiation a direct clinical priority. The study aimed to characterize the clinical-neurological condition of children with phenylketonuria and assess favorable outcomes associated with early dietary therapy. This observational clinical study included 25 patients aged 1–15 years. Clinical observation, a clinical case-series approach, and the chi-square test were used for analysis; mean age was M=8 years, standard deviation was SD=4.5 years, and the age range was 1–15 years. The protocol received ethics committee approval, and informed consent was obtained from the legal representatives of all children. Timely dietary therapy had been initiated in 100.0 % of participants; clinical-neurological status was favorable in 88.0 %, while 12.0 % retained signs requiring continued monitoring. Differences between categorical indicators reached statistical significance at p<0.001. The findings associate early adherence to dietary therapy with preservation of neurological functioning. The scientific contribution is the integrated description of timely dietary intervention, age distribution, and neurological outcomes within a clinically homogeneous group of children aged 1–15 years. In neurological practice, regular clinical monitoring and support for long-term adherence to therapeutic nutrition should remain priorities. Continued follow-up is needed to clarify the durability of preserved developmental indicators and to strengthen clinical interpretation of favorable outcomes in phenylketonuria.
Downloads
References
1. van Wegberg A.M.J., MacDonald A., Ahring K. et al. The complete European guidelines on phenylketonuria: diagnosis and treatment // Orphanet Journal of Rare Diseases. — 2017. — Vol. 12. — Art. 162. — P. 1–56. DOI: 10.1186/s13023-017-0685-2.
2. Blau N., van Spronsen F.J., Levy H.L. Phenylketonuria // The Lancet. — 2010. — Vol. 376. — № 9750. — P. 1417–1427. DOI: 10.1016/S0140-6736(10)60961-0.
3. van Spronsen F.J., Blau N., Harding C. et al. Phenylketonuria // Nature Reviews Disease Primers. — 2021. — Vol. 7. — Art. 36. — P. 1–23. DOI: 10.1038/s41572-021-00267-0.
4. Vockley J., Andersson H.C., Antshel K.M. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline // Genetics in Medicine. — 2014. — Vol. 16. — № 2. — P. 188–200. DOI: 10.1038/gim.2013.157.
5. Camp K.M., Parisi M.A., Acosta P.B. et al. Phenylketonuria Scientific Review Conference: state of the science and future research needs // Molecular Genetics and Metabolism. — 2014. — Vol. 112. — № 2. — P. 87–122. DOI: 10.1016/j.ymgme.2014.02.013.
6. De Giorgi A., Nardecchia F., Romani C., Leuzzi V. Metabolic control and clinical outcome in adolescents with phenylketonuria // Molecular Genetics and Metabolism. — 2023. — Vol. 140. — № 3. — Art. 107684. DOI: 10.1016/j.ymgme.2023.107684.
7. Bilder D.A., Noel J.K., Baker E.R. et al. Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria // Developmental Neuropsychology. — 2016. — Vol. 41. — № 4. — P. 245–260. DOI: 10.1080/87565641.2016.1243109.
8. Lindegren M.L., Krishnaswami S., Fonnesbeck C. et al. Adjuvant treatment for phenylketonuria // Comparative Effectiveness Review No. 56. — Rockville (MD): Agency for Healthcare Research and Quality, 2012. — AHRQ Publication No. 12-EHC035-EF. — P. 1–180.
9. MacDonald A., van Wegberg A.M.J., Ahring K. et al. PKU dietary handbook to accompany PKU guidelines // Orphanet Journal of Rare Diseases. — 2020. — Vol. 15. — Art. 171. — P. 1–30. DOI: 10.1186/s13023-020-01391-y.
10. Ney D.M., Stroup B.M., Clayton M.K. et al. Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial // The American Journal of Clinical Nutrition. — 2016. — Vol. 104. — № 2. — P. 334–345. DOI: 10.3945/ajcn.116.135293.
11. Strisciuglio P., Concolino D. New strategies for the treatment of phenylketonuria (PKU) // Metabolites. — 2014. — Vol. 4. — № 4. — P. 1007–1017. DOI: 10.3390/metabo4041007.
12. Burton B.K., Grange D.K., Milanowski A. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study // Journal of Inherited Metabolic Disease. — 2007. — Vol. 30. — № 5. — P. 700–707. DOI: 10.1007/s10545-007-0605-z.
13. Cleary M., Trefz F., Muntau A.C. et al. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes // Molecular Genetics and Metabolism. — 2013. — Vol. 110. — № 4. — P. 418–423. DOI: 10.1016/j.ymgme.2013.09.001.
14. De Groot M.J., Hoeksma M., Blau N. et al. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses // Molecular Genetics and Metabolism. — 2010. — Vol. 99. — № Suppl. 1. — P. S86–S89. DOI: 10.1016/j.ymgme.2009.10.016.
15. Anderson P.J., Wood S.J., Francis D.E. et al. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels? // Developmental Neuropsychology. — 2007. — Vol. 32. — № 2. — P. 645–668. DOI: 10.1080/87565640701375963.
16. Pietz J., Kreis R., Rupp A. et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria // Journal of Clinical Investigation. — 1999. — Vol. 103. — № 8. — P. 1169–1178. DOI: 10.1172/JCI5017.
17. Волгина С.Я., Яфарова С.Ш., Клетенкова Г.Р. Фенилкетонурия у детей: современные аспекты патогенеза, клинических проявлений, лечения // Российский вестник перинатологии и педиатрии. — 2017. — Т. 62. — № 5. — С. 111–118. DOI: 10.21508/1027-4065-2017-62-5-111-118.
18. Longo N., Arnold G.L., Pridjian G. et al. Long-term safety and efficacy of sapropterin: the PKUDOS registry experience // Molecular Genetics and Metabolism. — 2015. — Vol. 114. — № 4. — P. 557–563. DOI: 10.1016/j.ymgme.2015.02.003.
19. Singh R.H., Cunningham A.C., Mofidi S. et al. Updated, web-based nutrition management guideline for PKU: an evidence and consensus-based approach // Molecular Genetics and Metabolism. — 2016. — Vol. 118. — № 2. — P. 72–83. DOI: 10.1016/j.ymgme.2016.04.008.
20. Бушуева Т.В. Современный взгляд на проблему фенилкетонурии у детей: диагностика, клиника, лечение // Вопросы современной педиатрии. — 2010. — Т. 9. — № 1. — С. 157–160.
21. Бушуева Т.В., Боровик Т.Э. Современные принципы организации лечебного питания у детей разного возраста с фенилкетонурией // Вопросы современной педиатрии. — 2010. — Т. 9. — № 2. — С. 124–129.
22. Иринина Н.А., Иринин А.А. Эффективность использования специализированных аминокислотных смесей без фенилаланина для лечения больных фенилкетонурией // Российский педиатрический журнал. — 2015. — Т. 18. — № 6. — С. 10–13.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under this license:
- Share: Copy and redistribute the material in any medium or format
- Adapt: Remix, transform, and build upon the material for any purpose, including commercially
Attribution required: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
License URL: https://creativecommons.org/licenses/by/4.0/
Authors retain copyright of their work while granting the journal first publication rights.
